Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
This is a chart review of 200 Xofigo patients to describe sequencing and characterize clinical parameters and patient determinants that drive physician decision making.
Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart. Patients were at least 18 years of age as of the first diagnosis for mCRPC. Patients must have received at least one intravenous injection of Radium-223 (Xofigo).
First injection of Radium-223 must have started between periods
1-January-2014 to 30-June-2014 or 15-November-2014 to present.
Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose.
Exclusion Criteria:
Patients who received Radium-223 as part in an interventional clinical trial Actively treated, or expect to be treated, in 6 months before last follow-up, for any other malignancy with the exception of non-metastatic skin cancer or low-grade superficial bladder cancer.
